Please select the option that best describes you:
How do you approach using CD 19/20 levels to redose Rituximab for ANCA associated vasculitis?
- At what CD 19/20 level do you redose? Is this lab dependent?
- Do you also use these levels to instruct patients when to get vaccinated?
Answer from: at Community Practice
In the MAINRITSAN 2 trial, a tailored rituximab regimen adapted to ANCA-positivity or ANCA-titre change and/or circulating CD19+ B cell repopulation was compared with fixed-schedule rituximab infusions.There was no significant difference in relapse rates between the fixed-dose and tailored-do...
Sign in or Register to read more
Answer from: at Academic Institution
CD 19+B cell latency may serve as a surrogate for individualized therapy with Rituxan.